A recent study also reported that IL-22 resolved MASLD via the entry of IL-22R1 but not hepatic IL-22R1, as demonstrated by the finding that hepatocyte-specific Il22r1 ablation still responded to IL-22 therapy, resulting in reduced body and liver weights, decreased liver damage, and decreased collagen accumulation [213]. This evidence concerns the gene IL22RA1 and metabolic dysfunction-associated steatotic liver disease.